Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Biomaterials. 2021 May 25;275:120914. doi: 10.1016/j.biomaterials.2021.120914

Fig. 5. Improved efficacy is observed in the combination of eCPMV and R848.

Fig. 5.

A. Schematic of in situ vaccination strategy adapted from Fig 1c. 1.25×105 of B16F10 melanoma cells were injected intradermally on day −7. 100 ug of CPMV, eCPMV, or eCPMV + 40 ug of R848 was injected intratumorally on D0 and D7. Tumor growth was monitored every other day. B, C. ISV treatment with combination of eCPMV (100 ug) and R848 (40 ug) showed improved efficacy but is still inferior to CPMV (100 ug) in B16F10-tumor bearing mice (n=5). Tumor progression was monitored by measuring tumor surface area (length x width). Growth curves were analyzed using two-way ANOVA. survival curves were analyzed using log-rank (Mantel-Cox) test, p <0.05 as *, p <0.01 as **, and p <0.001 as ***. All experiments are repeated at least once with similar results.